

December 15, 2014

Interprotein Corporation

**Adoption of the subject that Interprotein has applied as  
a subject for A-STEP**

Interprotein Corporation (President, Masato HOSODA; Headquarters: Osaka, Japan; hereinafter “Interprotein”) announced today that the subject entitled “Drug discovery research of antimicrobial agent for *Helicobacter pylori* based on combinatorial chemistry” that Interprotein has applied in concert with Jichi Medical University was adopted as a subject (support type: FS Stage, Seeds Validation) in the second approval of 2014 for A-STEP (Adaptable & Seamless Technology Transfer Program through Target-driven R&D) by Japan Science and Technology Agency (JST).

The subjects that were adopted in the second approval of 2014 for A-STEP were listed in the following site: [http://www.jst.go.jp/a-step/kadai/h26-2fs\\_seeds\\_k.html](http://www.jst.go.jp/a-step/kadai/h26-2fs_seeds_k.html) (in Japanese).

Contact:  
Hirotsugu KOMATSU, Ph.D.  
CSO & Director  
R&D and BD Division  
Interprotein Corporation  
TEL/FAX: +81-(0)42-770-9477  
E-mail : [info@interprotein.com](mailto:info@interprotein.com)